MedBiquitous

Last Revised:
August 27, 2012

The ACCME views the FDA ER/LA Opioid Analgesic  REMS as an important initiative for addressing  a critical public health and patient safety concern. The ACCME believes that accredited CME can be an important factor in the success...

On July 9, the US Food and Drug Administration (FDA) released its Risk Evaluation and Mitigation Strategy or REMS for extended-release and long-acting (ER/LA) opioid analgesics.

The centerpiece of the ER/LA Opioid Analgesic...

Presentation about CE's role in ER/LA Opioid Analgesics REMS

The ...